TY - JOUR
T1 - Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence
AU - Lou, Carolyn
AU - Mitra, Nandita
AU - Wubbenhorst, Bradley
AU - D'Andrea, Kurt
AU - Hoffstad, Ole
AU - Kim, Brian S.
AU - Yan, Albert
AU - Zaenglein, Andrea L.
AU - Fuxench, Zelma Chiesa
AU - Nathanson, Katherine L.
AU - Margolis, David J.
N1 - Funding Information:
Disclosures: Andrea L. Zaenglein reported receiving research grants from Pfizer, Incyte, Abbvie, and Dermavant. Zelma Chiesa Fuxench reported serving as a consultant for the Asthma and Allergy Foundation of American and the National Eczema Association; receiving research grants from Regeneron, Sanofi, Tioga, Vanda, Realm therapeutics and Leo for work related to atopic dermatitis; and receiving honoraria for continuing medical education work in atopic dermatitis sponsored by educational grants from Sanofi and Regeneron. David Margolis reporting working as a consultant for Pfizer, Leo, and Sunovion with respect to studies of atopic dermatitis and serving on an advisory board for the National Eczema Association. No other disclosures were reported.Funding: This project has been funded in whole or in part by grants R01-AR060962 and R01-AR070873 from National Institute of Arthritis and Musculoskeletal and Skin Diseases (David Margolis, principle investigator). The Pediatric Eczema Elective Registry (PEER) studies were funded by Valeant Pharmaceuticals (David Margolis, principle investigator).
Funding Information:
Funding: This project has been funded in whole or in part by grants R01-AR060962 and R01-AR070873 from National Institute of Arthritis and Musculoskeletal and Skin Diseases (David Margolis, principle investigator). The Pediatric Eczema Elective Registry (PEER) studies were funded by Valeant Pharmaceuticals (David Margolis, principle investigator).
Publisher Copyright:
© 2019 American College of Allergy, Asthma & Immunology
PY - 2019/12
Y1 - 2019/12
N2 - Background: Atopic dermatitis (AD) is a common chronic relapsing skin disease. Genetic variants have been associated with skin barrier function and immune regulation. Thymic stromal lymphopoietin (TSLP), an immune regulator, has been previously associated with AD. Objective: To fine map TSLP and evaluate associations with the onset and persistence of AD. Methods: TSLP variation was determined using targeted massively parallel sequencing in a longitudinal cohort of children with AD. Evaluations included linkage disequilibrium and the persistence of AD for as many as 10 years of follow-up. The association between the presence of AD and rs1898671 variation was evaluated in a second independent cohort. Results: The minor variant frequency for rs1898671 was 23.5% (95% CI, 21.4%-25.8%). This variant was not in linkage disequilibrium with other TSLP variants in the longitudinal cohort (n = 741). White children with AD were less likely to have rs1898671 variant (odds ratio [OR], 1.41; 95% CI, 1.20-1.66) than Genome Aggregation Database controls. Children with AD and the rs1898671 variant during follow-up were more likely to have remission than children who were wild type for rs1898671 (OR, 1.56; 95% CI, 1.26-1.91). In the second cohort (n = 585), the rs1898671 variant was less prevalent in those with AD than those without. The protective effect was greater in rs1898671 heterozygotes (OR, 1.91; 95% CI, 1.34-2.75) than homozygotes (OR, 1.28; 95% CI, 0.61-2.70). Conclusion: TSLP and specifically rs1898671 are important in the pathogenesis of AD and could represent a potential clinical target for the development of therapies to treat individuals with AD.
AB - Background: Atopic dermatitis (AD) is a common chronic relapsing skin disease. Genetic variants have been associated with skin barrier function and immune regulation. Thymic stromal lymphopoietin (TSLP), an immune regulator, has been previously associated with AD. Objective: To fine map TSLP and evaluate associations with the onset and persistence of AD. Methods: TSLP variation was determined using targeted massively parallel sequencing in a longitudinal cohort of children with AD. Evaluations included linkage disequilibrium and the persistence of AD for as many as 10 years of follow-up. The association between the presence of AD and rs1898671 variation was evaluated in a second independent cohort. Results: The minor variant frequency for rs1898671 was 23.5% (95% CI, 21.4%-25.8%). This variant was not in linkage disequilibrium with other TSLP variants in the longitudinal cohort (n = 741). White children with AD were less likely to have rs1898671 variant (odds ratio [OR], 1.41; 95% CI, 1.20-1.66) than Genome Aggregation Database controls. Children with AD and the rs1898671 variant during follow-up were more likely to have remission than children who were wild type for rs1898671 (OR, 1.56; 95% CI, 1.26-1.91). In the second cohort (n = 585), the rs1898671 variant was less prevalent in those with AD than those without. The protective effect was greater in rs1898671 heterozygotes (OR, 1.91; 95% CI, 1.34-2.75) than homozygotes (OR, 1.28; 95% CI, 0.61-2.70). Conclusion: TSLP and specifically rs1898671 are important in the pathogenesis of AD and could represent a potential clinical target for the development of therapies to treat individuals with AD.
UR - http://www.scopus.com/inward/record.url?scp=85072573560&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2019.08.018
DO - 10.1016/j.anai.2019.08.018
M3 - Article
C2 - 31491540
AN - SCOPUS:85072573560
SN - 1081-1206
VL - 123
SP - 595-601.e1
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 6
ER -